Environmental tobacco smoke in the workplace: Markers of exposure, polymorphic enzymes and implications for disease state

Chemico-Biological Interactions

Volumn 146, Issue 3, 2003, Pages 211-224

  Collier, Abby C ^a   Pritsos, Chris A ^a  

^a UNIVERSITY OF NEVADA   (United States)

Author keywords

Disease state; Environmental tobacco smoke; Polymorphic enzymes

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; 4 BIPHENYLAMINE; 8 HYDROXYGUANINE; ACYLTRANSFERASE; BIOLOGICAL MARKER; CARCINOGEN; COTININE; CYTOCHROME P450 1A; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; GLUTATHIONE TRANSFERASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTATE DEHYDROGENASE; MYELOPEROXIDASE; NICOTINE; PEROXIDASE; POLYCYCLIC AROMATIC HYDROCARBON; SULFOTRANSFERASE; THYMINE DERIVATIVE; TOBACCO SMOKE; XENOBIOTIC AGENT;

APOPTOSIS; ASTHMA; CANCER GROWTH; CARDIOVASCULAR DISEASE; CATALYSIS; CELL CYCLE; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVATION; ENZYME ACTIVITY; FORCED EXPIRATORY VOLUME; GAS CHROMATOGRAPHY; GENETIC POLYMORPHISM; HEREDITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNE RESPONSE; LITERATURE; LUNG CANCER; MASS SPECTROMETRY; NEUTROPHIL; OCCUPATIONAL EXPOSURE; POLLUTANT; QUANTITATIVE ANALYSIS; RESPIRATORY BURST; RESPIRATORY TRACT DISEASE; SHORT SURVEY; WORK ENVIRONMENT;

NICOTIANA TABACUM;

EID: 0344430102     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2003.09.002     Document Type: Short Survey

References (103)

1. Roberts D. Natural tobacco flavor. Recent Adv. Tobacco Sci. 14:1988;49-81.
2. Weiss S., Utell M., Sarnett J. Environmental tobacco smoke exposure and asthma in adults. Environ. Health Perspect. 107:1999;891-895.
3. Misra D., Nguyen R.H.N. Environmental tobacco smoke and low birthweight: a hazard in the workplace? Environ. Health Perspect. 107:1999;897-906.
4. Kawachi I., Colditz A. Workplace exposure to passive smoking and risk of cardiovascular disease: summary of epidemiologic studies. Environ. Health Perspect. 107:1999;847-851.
5. Casto D., Schnapf B., Clotz M. Lack of effect of short-term passive smoking on the metabolic disposition of theophylline. Euro. J. Pharmacol. 39:1990;399-402.
6. Margolis P., Keyes L., Greenberg R., Bauman K., LaVange L. Urinary cotinine and parent history (questionnaire) as indicators of passive smoking and predictors of lower respiratory illness in infants. Pediatric Pulmonol. 23:1997;417-423.
7. Nowak D., Jorres R., Schmidt A., Magnussen H. Effect of 3. h passive smoke exposure in the evening on airway tone and responsiveness until next morning Int. Arch. Environ. Occup. Health. 69:1997;125-133.
8. Howard G., Thun M. Why is environmental tobacco smoke more strongly associated with coronary heart disease than expected? A review of potential biases and experimental data. Environ. Health Perspect. 107:1999;853-858.
9. Groh M.D., Morrison H. Environmental tobacco smoke and deaths from coronary heart disease in Canada. Chronic Dis. Canada. 23:2002;13-16.
10. State-specific prevalence of current cigarette smoking among adults and the proportion of adults who work in a smoke-free environment - United States, 1999, Morbidity Mortality Weekly Report 49 (2000) 978-982.
11. Nurminen M., Jaakkola M. Mortality from occupational exposure to environmental tobacco smoke in Finland. J. Occup. Environ. Med. 43:2001;687-693.
12. Brown K. Lung cancer and environmental tobacco smoke: occupational risk to non smokers. Environ. Health Perspect. 107:1999;885-890.
13. Heloma A., Jaakkola M., Kahkonen E., Reijula K. The short term impact of national smoke-free workplace legislation on passive smoking and tobacco use. Am. J. Public Health. 91:2001;1416-1418.
14. Jousilahti P., Helakorpi S. Prevalence of exposure to environmental tobacco smoke at work and at home - 15 year trends in Finland. Scandinavian J. Work Environ. Health. 28:2002;16-20.
15. Hayes R. The carcinogenicity of metals in humans. Cancer Causes Control. 8:1997;371-385.
16. Landrigan P., Baker D. The recognition and control of occupational disease. J. Am. Med. Assoc. 266:1991;676-680.
17. Mutti A. Biological monitoring in occupational and environmental toxicology. Toxicol. Lett. 108:1999;77-89.
18. Spengler J. Buildings operations and ETS exposure. Environ. Health Perspect. 107:1999;313-317.
19. Ott W. Human exposure assessment, the birth of a new science. J. Exp. Anal. Environn. Epidemiol. 5:1995;449-472.
20. Leaderer B., Hammond S. Evaluation of vapor phase nicotine and respiarble mass particles as markers of enviromental tobacco smoke. Environ. Sci. Technol. 25:1991;770-777.
21. Muller C., England W. Achieving your indoor air quality goals which filtration system works best? J. Am. Soc. Heat. Refrig. Aircondition. 37:1995;8-10.
22. Jaakkola M., Sarnet J. Occupational exposure to environmental tobacco smoke and health risk assessment. Environ. Health Perspect. 107:1999;829-835.
23. Lee P., Forey B. Misclassification of smoking habits as a source of bias in the study of environmental tobacco smoke and lung cancer. Stat. Med. 15:1996;581-605.
24. Al-Delaimy W., Fraser T., Woodward A. Nicotine in the hair of bar and restaurant workers. New Zealand Med. J. 114:2001;80-83.
25. Benowitz N., Jacob P. Nicotine and cotinine elimination pharmacokinetics in smokers and non smokers. Clin. Pharmacol. Therap. 53:1993;316-323.
26. Benowitz N., Jacob P. Metabolism of nicotine to cotinine performed by a dual stable isotope method. Clin. Pharmacol. Therap. 56:1994;483-493.
27. Kyerematen G., Morgan M., Chattopadhyay B., Bethizy J.D., Vesell E. Disposition of nicotine and eight metabolites in smokers and nonsmokers: identification in smokers of two metabolites that are longer lived than cotinine. Clin. Pharmacol. Therap. 48:1990;641-651.
28. Tricker A. Nicotine metabolism. Toxicology. 183:2003;151-173.
29. Flammang A., Gelboin H., Aoyama T., Gonzalez F., McCoy G. Nicotine metabolism by cDNA expressed cytochrome P450s. Biochem. Arch. 8:1992;1-8.
30. Yang M., Kunugita N., Kitagawa K., Kang S., Coles B., Kadlubar F., Katoh T., Matsuno K., Kawamoto T. Individual difference in urinary cotinine levels in Japanese smokers: relation to genetic polymorphism of drug metabolising enzymes. Cancer Epidemiol. Biomarkers Prevent. 10:2001;589-593.
31. Emmons K., Agrams D., Marshall R., Marcus B., Kane M., Novotna B., Etzel R. An evaluation of the relationship between self-report and biochemical measures of environmental tobacco smoke exposure. Prevent. Med. 23:1994;35-39.
32. Benowitz N. Cotinine as a biomaker of environmental tobacco smoke exposure. Epidemiol. Rev. 18:1996;188-204.
33. Davis R., Stiles M., deBethizy J., Reynolds J. Dietary nicotine: a source of unrinary cotinine. Food Chem. Toxicol. 29:1991;821-827.
34. Bianchini F., Donato F., Faure H., Ravanat J.-L., Hall J., Cadet J. Urinary excretion of 5-(hydroxymethyl)uracil in healthy volunteers: effect of active and passive tobacco smoke. Int. J. Cancer. 77:1998;40-46.
35. Crawford B., Mayer J., Santella R., Cooper T., Ottman R., Tsai W., Simon-Cereijido G., Wang M., Tang D., Perera F. Biomarkers of environmental tobacco smoke in preschool children and their mothers. J. Natl. Cancer Inst. 86:1994;1398-1402.
36. Atawodi S., Lea S., Nyberg F., Mukeria A., Constantinescu V., Ahrens W., Brueske-Hohlfeld I., Fortes C., Bofetta P., Friesen M. 4-hydroxy-1-(3-pyridyl)- 1-butanone-hemoglobin adducts as biomarkers of exposure to tobacco smoke: validation of a method to be used in multicenter studies. Cancer Epidemiol. Biomarkers Prevent. 7:1998;817-821.
37. Perera F. Molecular epidemiology and prevention of cancer. Environ. Health Perspect. 103:1995;233-236.
38. Scherer G., Richter E. Biomonitoring exposure to environmental tobacco smoke (ETS): a critical reappraisal. Hum. Exp. Toxicol. 16:1997;449-459.
39. Cadet J., D'Ham C., Douki T., Poujet J., Ravanat J., Sauviago S. Facts and artifacts in the measurement of oxidative base damage to DNA. Free Radic. Res. 29:1998;541-550.
40. Hecht S., Carmella S., Murphy S., Akerkar S., Brunneman K., Hoffmann D. A tobacco-specific lung carcinogen in the urine of men exposed to cigarette smoke. New Engl. J. Med. 329:1993;1543-1546.
41. Dang L., McQueen C. Mutagenicity of 4-aminobiphenyl and 4-acetylaminobiphenyl in Salmonella typhimurium strains expressing different levels of N-acetyltransferase. Toxicol. Appl. Pharmacol. 159:1999;77-82.
42. Vineis P., Bartsch H., Caporaso N., Harrington A., Kadlubar F., Landi M., Malaveille C., Shields P., Skipper P., Talaska G. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature. 369:1994;154-156.
43. Wortley P., Carabello R., Pederson L., Pechacek T. Exposure to second hand smoke in the workplace: serum cotinine by occupation. J. Occup. Environ. Med. 44:2002;503-509.
44. King G., Strouse R., Hoevy D., Zehe L. Cigarette smoking in Conneticut: home and workplace exposure. Conneticut Med. 62:1998;531-539.
45. Knutsson A., Nilsson T. Tobacco use and exposure to environmental tobacco smoke in relation to certain work characteristics. Scand. J. Soc. Med. 26:1998;183-189.
46. Boffetta P. Involuntary smoking and lung cancer. Scand. J. Work Environ. Health. 2:2002;30-40.
47. Masjedi M., Kazemi H., Johnson D. Effects of passive smoking on pulmonary function of adults. Thorax. 45:1990;27-31.
48. Janson C., Chinn S., Jarvis D., Zock J.P., Torén K., Burney P. Effect of passive smoking on respiratory symptoms, bronchial responsiveness, lung function, and total serum IgE in the European Community Respiratory Health Survey: a cross-sectional study. Lancet. 358:2001;2103-2109.
49. Karol M. Respiratory allergy: what are the uncertainties? Toxicology. 181-182:2002;305-310.
50. Moffatt R., Stamford B., Biggerstaff K. Influence of worksiteenvironmental tobacco smoke on serum lipoprotein profiles of female nonsmokers. Metabolism. 44:1995;1536-1539.
51. Mizoue T., Ueda R., Hino Y., Yoshimura T. Workplace exposure to environmental tobacco smoke and high density lipoprotein cholesterol among non-smokers. Am. J. Epidemiol. 150:1999;1068-1072.
52. Whig J., Singh C., Soni G., Bansal A. Serum lipids and lipoprotein profiles of cigarette smokers and passive smokers. Indian J. Med. Res. 96:1992;282-287.
53. Nygard O., Vollset S., refsum H., Stensvold I., Tverdal A., Nordrehaug J., Ueland M., Kvale G. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. J. Am. Med. Assoc. 274:1995;1526-1533.
54. Das I. Raised C-reactive protein levels in serum from smokers. Clin. Chim. Acta. 153:1985;9-13.
55. Jensen E., Fusch C., Jaeger P., Peheim E., Horber F. Impact of chromic cigarette smoking on body composition and fuel metabolism. J. Clin. Endocrinol. Metabol. 80:1995;2181-2185.
56. Wallenfeldt K., Hulthe J., Bokemark L., wikstrand J., Fagerberg B. Carotid and femoral athersclerosis, cardiovascualr risk factors and C-reactive protein in relation to smokeless tobacco use or smoking in 58 year old men. J. Int. Med. 250:2001;492-501.
57. Martin N., Bowen L.D., Cutter G., Clodfelter S., Pritsos C. Blood homocysteine (HCY) levels in non-smokers exposed to environmental tobacco smoke (ETS) and the effect of polymorphisms int he glutathione-S-transferase M (GSTM) glutathione-S-transferase T (GSTT) and NAD(P)H quinone oxidoreductase (NQO1) genes. The Toxicologist. 72:2003;186.
58. Howard D., Ota R., Briggs L., Hampton M., Ca C.P. Oxidative stress induced by environmental tobacco smoke in the workplace is mitigated by antioxidant supplementation. Cancer Epidemiol. Biomarkers Prevent. 7:1998;981-988.
59. Howard D., Ota R., Briggs L., Hampton M., Pritsos C. Environmental tobacco smoke in the workplace induces oxidative stress in employees, including increased production of 8-hydroxy-2′-deoxyguanosine. Cancer Epidemiol. Biomarkers Prevent. 7:1998;141-146.
60. Their R., Brüning T., Roos P., Bolt H. Cytochrome P450 1B1, a new keystone in gene-environment interactions related to human head and neck cancer. Arch. Toxicol. 76:2002;249-256.
61. Nebert D., Row A., Dieter M., Solis W., Yang Y., Dalton T. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control and apoptosis. Biochem. Pharmacol. 59:2000;65-85.
62. Williams J. Single nucleotide polymorphisms, metabolic activation and environmental carcinogenesis: why molecular epidemiologists should think about enzyme expression. Carcinogenesis. 22:2001;209-214.
63. Degawa M., Tanimura S., Agatsuma T., Hashimoto Y. Hepatocarcinogenic heterocyclic aromatic amines that induce cytochrome P-448H isozymes, mainly cytochrome P-448H (P4501A2). Responsible for the mutagenic activation of the carcinogens in rat liver. Carcinogenesis. 10:1989;1119-1122.
64. Kao S.-Y., Wu C.-H., Lin S.-C., Yap S.-K., Chang C.-S., Wong Y.-K., Chi L.-Y., Liu T.-Y. Genetic polymorphism of cytochrome P4501A1 and susceptibility to oral squamous cell carcinoma and oral precancer lesions associated with smoking/betel use. J. Oral Pathol. Med. 31:2002;505-511.
65. Ivaschenko T., Sideleva O., Baranov V. Glutathione-S-transferase mu and theta gene polymorphisms as new risk factors for atopic bronchial asthma. J. Mol. Med. 80:2002;39-43.
66. Wedlund P., Kimura S., Gonzalez F., Nebert D. I462V mutation in the human CYP1A1 gene: lack of correlation with either the Msp I kb (M2) allele or CYP1A1 inducibility in a three-generation family of East Mediterranean descent. Pharmacogenetics. 4:1994;21-26.
67. Cosma G., Crofts F., Currie D., wirgin I., Toniolo P., Garte S. Racial differences in restriction fragment polymorphisms and messenger RNA of the human CYP1A1 gene. J. Toxicol. Environ. Health. 40:1993;309-316.
68. Smith G., Harper P., Wong J., Lam M., Reid K., Petsikas D., Massey T. Human lung micorosomal cytochrome P450 1A1 (CYP1A1) activities: Impact of smoking status and CYP1A1, Aryl hydrocarbon receptor and glutathione-S- transferase M1 genetic polymorphisms. Cancer Epidemiol. Biomarkers Prevent. 10:2001;839-853.
69. Sachse C., Bhambra U., Smith G., Lightfoot T., Barrett J., Scollay J., Garner R., Boobis A., Wolf C., Gooderham N., Group C.C.S. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br. J. Clin. Pharmacol. 55:2003;68-76.
70. Lang N., Butler M., Massengill J., Lawson M., Stotts R., Hauer-Jensen M., Kadlubar F. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol. Biomarkers Prevent. 3:1994;675-682.
71. Sachse C., Brockmöller J., Bauer S., Roots I. Functional significance of a C/A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J Clin. Pharmacol. 47:1999;445-449.
72. Frye R., Schneider V., Frye C., Feldman A. Plasma levels of TNF and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J. Cardiac Failure. 8(5):2002;315-319.
73. Long D., Jaiswal A. NRH:quinone oxidoreductase 2 (NQO2). Chemico-Biol. Interact. 129:2000;99-112.
74. Traver R., Horikoshi T., Danenberg K., Stadlbauer T., Danenberg P., Ross D., Gibson N. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 52:1992;797-802.
75. Krajinovic M., Sinnett H., Richer C., Labuda D., Sinett D. Role of NQO1, MPO and CYP2E1 genetic polymorphisms int eh susceptibility to childhood acute lymphoblastic leukemia. Int. J. Cancer. 97:2002;230-236.
76. Sunaga N., Kohno T., Yanagitani N., Sugimura H., Kunitoh H., Tamura T., Takei Y., Tsuchiya S., Saito R., Yokota J. Contribution of NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility. Cancer Epidemiol. Biomarkers Prevent. 11:2002;730-738.
77. Longuemaux S., Deloménie C., Gallou C., Méjean A., Vincent-Viry M., Bouvier R., Droz D., Krishnamoorthy R., Galteau M.-M., Junien C., Béroud C., Dupret J.-M. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic metabolising enzymes. Cancer Res. 59:1999;2903-2908.
78. Brockstedt U., Krajinovic M., Richer C., Mathonnet G., Sinnett D., Pfau W., Labuda D. Analyses of bulky DNA adduct levels I human breast tussye and genetic polymorphisms of cytochromes P450 (CYPs), myeloperoxidase (MPO), quinone oxidoreductase (NQO1) and glutathione-S-transferases (GSTs). Mutat. Res. 516:2002;41-47.
79. Nebert D., Roe A., Vandale S., Bingham E., Oakley G. NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet. Med. 4:2002;62-70.
80. Hein D., McQueen C., Grant D., Goodfellow G., Kadlubar F., Weber W., Weber W. Drug Metabol. Disposition. 28:2000;1425-1432.
81. Raunio H., Husgafvel-Pursiainen K., Anttila S., Hietanen E., Hirvonen A., Pelknoen O. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility - a review. Gene. 159:1995;113-121.
82. Hoffmann D., Rivenson A., Amin A., Hecht S. Dose response study of the carcinogenicity of tobacco-specific N-nitrosamines in F344 rats. J. Cancer Clin. Res. Oncol. 108:1984;81-86.
83. Nyberg F., Hou S.-M., Hemminki K., Lambert B., Pershagen G. Glutathione S-transferase 1 and N-acetyl transferase 2 genetic polymorphisms and exposure to tobacco smoke in smoking and non-smoking lung cancer patients and population controls. Cancer Epidemiol. Biomarkers Prevent. 7:1998;883-895.
84. Nacak M., Aynaciogly A., Filiz A., Cascorbi I., Erdal M., Yilmaz N., Ekinci E., Roots I. Association between N-acetylation genetic polymorphism and bronchial asthma. Br. J. Clin. Pharmacol. 54:2002;671-674.
85. Siedergard J., Pero R., Miller D., Beattie E. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis. 7:1986;751-753.
86. Bell D., Taylor J., Paulson D., Robertson E., Mohler J., Lucier J. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione-S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J. Cancer Clin. Res. Oncol. 85:1993;1159-1164.
87. Hirvonen A., Nylund L., Kociba P., Husgafvel-Pursiainen K., Vainio H. Modulation or urinary mutagenicity by genetically determined carcinogen metabolism in smokers. Carcinogenesis. 15:1994;1767.
88. Bowen L., Cutter G., Clodfelter S., Pritsos C. Serum oxidised LDL levels are increased in nonsmokers exposed to environmental tobacco smoke (ETS) and associated with genetic polymorphisms in GST-T, GST-M and NQO1. The Toxicologist. 72:2003;186.
89. Malats N., Camus-Radon A.-M., Nyberg F., Ahrens W., Constantinescu C., Mukeria A., Benhamou S., Batura-Gabryel H., Bruske-Hohlfeld I., Simonato L., Menezes A., Lea S., Lang M., Boffetta P. Lung cancer risk in nonsmokers and GSTM1 and GSTT1 genetic polymorphism. Cancer Epidemiol. Biomarkers Prevent. 9:2000;827-833.
90. Miller D., Vivo I.D., Neuberg D., Wain J., Lynch T., Su L., Christiani D. Association between self-reported environmental tobacco smoke exposure and lung cancer:modification by GTSP1 polymorphism. Int. J. Cancer. 104:2003;758-763.
91. McCarver D., Hines R. The ontogeny of human drug metabolsing enzymes: phase II. Conjugation enzymes and regulatory mechanisms. J. Pharmacol. Exp. Therap. 300:2002;361-366.
92. J. Williams, E. Stone, G. Fakis, N. Johnson, W. Meinl, H. Glatt, E. Sim, D. Phillips, Human mammary NAT and SULT enzyme metabolically activate N-hydroxylated heterocyclic amines, but NAT enzyme activity is not influenced by NAT genotype, Proc. Am. Assoc. Cancer Res. 41 (2000).
93. Coughtrie M., Gilissen R., Shek B., Strange R., Fryer A., Jones P., Bamber D. Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem. J. 337:1999;45-49.
94. Nguyen H., Finkelstein E., Reznick A., Cross C., Vliet A.V.D. Cigarette smoke impairs neutrophil respiratory burst activation by aldehyde-induced thiol modifications. Toxicology. 160:2001;207-217.
95. London S., Lehman T., Taylor J. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res. 57:1997;5001-5003.
96. Kritz H., Schmid P., Sinzinger H. Passive smoking and cardiovascular risk. Arch. Intern. Med. 155:1995;1942-1948.
97. Aviado D. Cardiovascular disease and exposure to environmental tobacco smoke. Am. Ind. Hyg. Assoc. J. 57:1996;285-294.
98. Banegas J., Rodriguez-Artalejo R., Graciani A., Villar F., Herruzo R. Mortality attributable to cardiovascular risk factors in Spain. Euro. J. Clin. Nutr. 57:2003;S18-S21.
99. Critchley J., Capewell S., Unal B. Life years gained from coronary heart disease mortality reduction in sctoland: prevention or treatment? J. Clin. Epidemiol. 56:2003;583-590.
100. Glantz S., Parmley W. Passive smoking and heart disease. Clin. Cardiol. 273:1995;1047-1053.
101. Steenland K., Thun M., Lally C., Heath C. Environmental tobacco smoke and coronary heart disease in the American Cancer Society CPS-II cohort. Circulation. 94:1996;622-628.
102. Wilson N., Thompson G. Still dying from second-hand smike at work: a brief review of the evidence from smoke-free workplaces in New Zealand. New Zealand Med. J. 115:2002;U240.
103. Forastiere F., Presti E.L., Agabiti N., Rapiti E., Perucci C. Health impact of exposure to environmental tobacco smoke in Italy. Epidemiol. Prevent. 26:2002;18-29.